Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Neurology|September 5, 2020
Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathyAndria L Ford, Victoria W Chin, Slim Fellah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, S Peter Kang, Drew Rasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Plos Genetics|April 13, 2011
Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesisJin Woo Choi, Dae Gyu Kim, Al-Eum Lee, et al.
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Nature Genetics|July 5, 2011
Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individualsYoung Seok Ju, Jong-Il Kim, Sheehyun Kim, et al.
JAMA Oncology|September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical TrialKohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A Shah, Kei Muro, et al.
Pageof 9